| Literature DB >> 30497337 |
Bogdan Ionel Vatu1, Stefan-Alexandru Artene1, Adeline-Georgiana Staicu1, Adina Turcu-Stiolica2, Catalin Folcuti1, Alexandra Dragoi1, Catalina Cioc1, Stefania-Carina Baloi1, Ligia Gabriela Tataranu3, Cristian Silosi4, Anica Dricu1.
Abstract
In recent years, immunotherapy has raised the interest of many studies and provided different perspectives for the therapeutic management of high grade glioma. Our meta-analysis focused on the effectiveness of dendritic cell (DC) therapy and viral therapy (VT) in clinical trials. Fourteen eligible studies have been evaluated and the results suggest the improvement of both OS (HR = 0.65) (p < 0.0001) and PFS (HR = 0.59) (p = 0.01) for patients receiving DC therapy. The data for VT showed a slight improvement in terms of OS (HR = 0.81), while PFS was similar to the control arms (HR = 1.06) (p = 0.41).Entities:
Keywords: High grade glioma; dendritic cells; glioblastoma; immunotherapy; meta-analysis; viral therapy
Mesh:
Year: 2018 PMID: 30497337 DOI: 10.1080/15321819.2018.1551804
Source DB: PubMed Journal: J Immunoassay Immunochem ISSN: 1532-1819